Roobcio /
4 February 2016Americas

AstraZeneca says Crestor patent expiry will hit sales

AstraZeneca has predicted a dip in revenue this year after it loses patent exclusivity on its anti-cholesterol drug Crestor (rosuvastatin calcium).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at